City residents must take primary responsibility for the conditions of their properties and neighborhoods, Reading’s community development director says. “Your constituents have the primary ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

You face real maintenance and sustainability issues when ceding coding control to AI. Having AI agents write your code is a lot like having human contractors write it. These best practices will help ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...

Developers using the latest versions of AI coding tools like Claude Code, Cursor CLI, Gemini CLI, and CoPilot CLI could inadvertently execute malicious code on their systems with a single keypress, or ...

Since debuting last spring, OpenAI's Codex coding app has seen standalone Mac and Windows releases, so it was only a matter of time before OpenAI gave people a way to access their Codex projects on ...

In The Lancet in 1971, Julian Tudor Hart gave medicine one of its most important insights: the availability of medical care ...

xAI has launched a coding agent of its own to serve as competitor to its rivals' products, such as Anthropic's Claude Code. It's called Grok Build, and it's still in its early beta version that's ...

Whether they are competing approaches or complementary, there are good ways to incorporate both these AI-based methods into developing resilient applications. Vibe coding and spec-driven development ...

Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...

Earlier this year, Recursion Pharmaceuticals Inc RXRX initiated discussions with the FDA for the design of a registrational study for its experimental drug REC-4881 in familial adenomatous polyposis ...